www.jdvat.org Review Article

JOURNAL of DRUG VIGILANCE and ALTERNATIVE THERAPIES

A PEER REVIEWED OPEN ACCESS JOURNAL

J Drug Vigil Altern Ther. 2022 Dec 30; 2(2):56-81. DOI: 10.52816/JDVAT.2022.2203

From Biomarkers to Pharmacological Targets: Long Non-Coding RNAs in Disease Intervention and Drug Development

Akula Sushma Sri Valli*

Department of Biotechnology, Gautami Degree College, Osmania University, Hyderabad, Telangana, India – 501218.

ABSTRACT

The realm of molecular biology has witnessed a paradigm shift with the discovery and elucidation of the intricate world of long non-coding RNAs (lncRNAs). LncRNAs have emerged as key players in the orchestration of cellular processes and, more importantly, as potential biomarkers and pharmacological targets for a myriad of diseases. In various diseases, such as cancer, neurodegenerative disorders, and cardiovascular conditions, specific lncRNAs emerge as critical regulators impacting cell proliferation, apoptosis, and immune response. The review extends to the evolving field of lncRNA therapeutics, exploring strategies for effective delivery, overcoming absorption challenges, and addressing issues related to metabolism. This comprehensive review delves into the evolving landscape of lncRNAs, exploring their diverse roles in health and disease, and highlighting their promise as diagnostic biomarkers and therapeutic targets in drug development.

Keywords: LncRNAs, biomarkers, epigenetic regulation, disease intervention, therapeutic targets, drug development.

1. INTRODUCTION

Long non-coding RNAs (lncRNAs) represent a class of RNA molecules characterized by their extended length (exceeding 200 nucleotides) and lack of protein-coding capacity. Unlike messenger RNAs (mRNAs) that serve as templates for protein synthesis, lncRNAs were initially considered as transcriptional noise or non-functional byproducts of genome activity. However, over the years, research has revealed that lncRNAs play crucial roles in the regulation of gene expression and various cellular processes.[1]

LncRNAs are transcribed from DNA but do not undergo translation to produce proteins. Instead, they engage in diverse molecular functions, acting as regulators, modulators, and scaffolds in cellular processes.[2] Their involvement spans multiple levels of gene expression control, including chromatin organization, transcriptional regulation, post-transcriptional processing, and epigenetic modifications. These molecules have been implicated in a wide array of biological processes and are associated with various diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and more. The discovery and characterization of lncRNAs have transformed our understanding of the complexity of the genome and its functional elements beyond protein-coding genes.[3]

The intricate mechanisms of lncRNAs enable their participation in nearly all physiological processes within living cells, and they are linked to a diverse range of diseases. The study of lncRNAs has become a burgeoning field in molecular biology, with ongoing research aimed at deciphering their specific functions, mechanisms of action, and potential therapeutic applications (Fig. 1). As researchers continue to unravel the intricacies of lncRNA biology, these molecules are increasingly recognized for their significant contributions to cellular

***Corresponding Author:** akulasushma09@gmail.com

Received: 15 July 2022 **Revised:** 02 Aug 2022 **Accepted:** 05 Sep 2022

regulation and their potential implications in health and disease. Given their pivotal roles in diseases, researchers are actively developing technologies and tools to target lncRNAs for the creation of lncRNA-based drugs. This presents a significant opportunity and a novel frontier in drug development. This review offers an overview of the swift progress made in this field over the past few years, delving into the realms of pharmacokinetics, toxicities, and strategies for overcoming persistent challenges.



Fig. 1: Classification, mechanism of action, pharmacological targeting, and toxicities of LncRNAs

2. DEVELOPMENT & CLASSIFICATION OF lncRNA RESEARCH

During the early stages of genomics and transcriptomics in the 1990s and early 2000s, scientific focus was primarily directed towards protein-coding genes, often disregarding non-coding regions of the genome as transcriptional noise. While the discovery of small non-coding RNAs, such as microRNAs, hinted at the existence of functional non-coding RNAs, the broader category of lncRNAs was not extensively studied at this juncture.

Advancements in high-throughput sequencing technologies during the 2000s facilitated genome-wide transcriptome studies, revealing a multitude of transcripts that did not possess protein-coding capabilities. This marked the initial recognition of the abundance and diversity of lncRNAs in the genome. As the 2010s unfolded, researchers delved into the functional characterization of lncRNAs, elucidating their roles in the regulation of gene expression, chromatin organization, and other pivotal cellular functions. Specific lncRNAs were identified as key players in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

The subsequent decade witnessed remarkable technological strides, such as CRISPR-Cas9 gene editing and single-cell RNA sequencing, enabling more precise studies of lncRNA function and mechanisms. Researchers began to unravel the intricate interactions between lncRNAs, proteins, and other cellular components. The 2020s ushered in an era of exploring the therapeutic potential of lncRNAs, with growing interest in targeting specific lncRNAs for drug development, particularly in diseases where dysregulation of gene expression is a critical factor.[4-7]

The classification of lncRNAs is based on their genomic location, functions, and mechanisms of action, revealing the complexity of their roles in gene regulation.

- Intergenic lncRNAs, situated between protein-coding genes in intergenic regions, contribute to the regulation of nearby genes. They can influence chromatin interactions and gene expression in their genomic vicinity, showcasing their role in local gene regulation.
- Intronic lncRNAs are embedded within the introns of protein-coding genes. While residing within

host genes, they may affect splicing patterns or expression levels. Intronic lncRNAs can have independent functions, inducing cellular processes beyond the regulation of their host genes.

- Sense and antisense lncRNAs are transcribed from the same DNA strand as protein-coding genes or the opposite strand, respectively. These lncRNAs can modulate the expression of their analogous sense or antisense counterparts, adding an additional layer of complexity to gene regulation.
- Enhancer lncRNAs are transcribed from enhancer regions of the genome. They play a crucial role in enhancing the activity of specific genes by interacting with promoters or chromatin. This involvement in the regulation of gene enhancers underscores their importance in shaping gene expression patterns.
- Pseudogene-derived lncRNAs, originating from pseudogenes, share sequence similarities with functional genes but lack protein-coding potential. They can regulate gene expression or act as competitors with functional genes, influencing cellular processes in unique ways.
- Circular lncRNAs, characterized by a covalently closed loop structure, exhibit increased stability due to resistance against exonucleases. These lncRNAs can participate in diverse regulatory mechanisms, contributing to the complexity of non-coding RNA functions.
- Transcribed Ultraconserved Regions (T-UCRs) constitute a class of highly conserved lncRNAs transcribed from ultraconserved genomic regions. Their conservation across species suggests potential regulatory roles in fundamental cellular processes.
- Long Intergenic Non-Coding RNAs (lincRNAs) are transcribed from intergenic regions and form a broad category with diverse functions. They participate in chromatin remodeling, transcriptional regulation, and cellular signaling, showcasing the versatility of lincRNAs.
- Nuclear retained lncRNAs are primarily localized in the cell nucleus, where they may play roles in chromatin organization, transcriptional regulation, or splicing. These lncRNAs contribute to nuclear processes critical for gene expression control.
- Cytoplasmic lncRNAs, predominantly found in the cytoplasm, exert their influence on post-transcriptional processes. They can regulate mRNA stability, translation, and protein localization, showcasing their involvement in diverse cellular mechanisms.[8-12]

3. MECHANISMS OF ACTION

While the study of lncRNAs has provided valuable insights into their diverse mechanisms of action, several challenges and complexities exist in understanding and deciphering these mechanisms (Fig. 2). The processes through which lncRNAs control gene expression is intricate and remain not completely understood at present.[13]

3.1 Chromatin Remodeling

LncRNAs interact with chromatin-modifying complexes, influencing chromatin structure and accessibility. Acting as scaffolds, they guide these complexes to specific genomic loci, resulting in changes in histone modifications and overall chromatin organization. The lncRNA XIST (X-inactive-specific transcript) is known for its role in X chromosome inactivation in females. XIST interacts with chromatin-modifying complexes, such as Polycomb Repressive Complex 2 (PRC2), guiding them to the inactive X chromosome. This results in changes in histone modifications, leading to transcriptional silencing of genes on the inactive X chromosome.[14,15]

3.2 Transcriptional Regulation

LncRNAs directly impact the transcriptional activity of genes by interacting with transcription factors or RNA polymerase. They can function as enhancers, promoters, or inhibitors of transcription, thereby modulating the expression of nearby or distantly located protein-coding genes. The lncRNA HOTAIR (HOX Transcript Antisense Intergenic RNA) is involved in regulating gene expression in the HOX gene cluster. HOTAIR interacts with PRC2 and LSD1 complexes, influencing the transcriptional activity of genes in the HOX cluster. This modulation contributes to the regulation of developmental processes.[16-18]

3.3 Epigenetic Regulation

LncRNAs participate in epigenetic modifications, including DNA methylation and histone modification. By recruiting epigenetic modifiers to specific



TF: *transcription factor;* ***CR:*** *chromatin remodelling;* ***SR:*** *splicing regulatory*

Fig. 2: Different mechanism of action of LncRNA

genomic regions, lncRNAs influence the epigenetic landscape, leading to consequential changes in gene expression. The lncRNA ANRIL (Antisense Non-coding RNA in the INK4 Locus) is associated with the regulation of the INK4b-ARF-INK4a gene cluster. ANRIL recruit's chromatin-modifying complexes to the INK4b-ARF-INK4a locus, leading to changes in DNA methylation and histone modifications. This epigenetic regulation is implicated in cancer and atherosclerosis.[19,20]

3.4 Post-Transcriptional Regulation

LncRNAs regulate mRNA stability and translation by interacting with messenger RNAs (mRNAs). They act as competitive endogenous RNAs (ceRNAs), sequestering microRNAs and modulating mRNA stability and translation by preventing microRNAs from binding to target mRNAs. The lncRNA MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) regulates alternative splicing and mRNA stability. MALAT1 interacts with serine/arginine-rich splicing factors, influencing alternative splicing events. Additionally, it modulates mRNA stability by interacting with target mRNAs, impacting cancer-related processes.[21]

3.5 Modulation of Protein Activity

LncRNAs directly interact with proteins, influencing their activity or stability. Serving as molecular scaffolds, lncRNAs bring together proteins involved in specific cellular processes, thereby modulating their interactions and functions. The lncRNA NEAT1 (Nuclear Enriched Abundant Transcript 1) forms paraspeckles in the nucleus and interacts with proteins involved in transcriptional regulation. NEAT1 acts as a scaffold, bringing together RNA-binding proteins and influencing their activity. This modulates gene expression and cellular responses.[22]

3.6 Subcellular Localization

LncRNAs control the subcellular localization of proteins or other RNAs. They guide molecules to specific cellular compartments, exerting influence over local cellular processes. The lncRNA MALAT1 also plays a role in controlling the subcellular localization of RNAs. MALAT1 interacts with pre-mRNAs and guides them to nuclear speckles, influencing RNA processing. The subcellular localization controlled by MALAT1 affects cellular functions such as gene expression and RNA processing.[23,24]

3.7 Alternative Splicing

LncRNAs impact alternative splicing events, contributing to the generation of different mRNA isoforms. Through interactions with splicing factors, lncRNAs influence the splicing process and contribute to the diversity of the cellular transcriptome. The lncRNA TUG1 (Taurine-Upregulated Gene 1) regulates alternative splicing in

various genes. TUG1 interacts with splicing factors, influencing splice site selection, and leading to the generation of different mRNA isoforms. Dysregulation of TUG1 is implicated in diseases, including cancer.[25,26]

3.8 Ribonucleoprotein Complex

LncRNAs form ribonucleoprotein complexes with proteins, regulating various cellular functions. These complexes play roles in RNA processing, transport, translation, and other essential cellular processes. The lncRNA H19 forms ribonucleoprotein complexes with the protein YB-1, contributing to cellular processes. The H19-YB-1 complex is involved in mRNA translation regulation, impacting the expression of genes related to cell growth and proliferation.[27]

4. PHARMACOLOGICAL TARGETING OF LncRNAs

Pharmacological targeting of lncRNAs has emerged as a promising avenue for therapeutic intervention, offering potential strategies to modulate gene expression and influence cellular processes. The unique regulatory roles played by lncRNAs in various diseases make them attractive targets for drug development. Several approaches have been explored to pharmacologically target lncRNAs:

4.1 Antisense Oligonucleotides (ASOs)

Antisense oligonucleotides (ASOs), as synthetic entities designed for precise molecular interactions, have demonstrated versatility in targeting specific lncRNAs with therapeutic implications.[28] One compelling example of the therapeutic potential of ASOs lies in their application against MALAT1, a prominent lncRNA associated with various cellular processes, including cancer development. ASOs designed to specifically target MALAT1 have demonstrated promising outcomes in impeding cancer cell proliferation. Through the precise interaction with MALAT1, these ASOs contribute to the modulation of its expression levels or function, thereby offering a potential avenue for therapeutic intervention in cancer treatment.[29]

ASOs designed to target the lncRNA HOTAIR, known for its involvement in metastasis and chromatin remodeling, have shown promise in impeding the progression of certain cancers. By disrupting HOTAIR's regulatory influence, these ASOs contribute to the suppression of metastatic processes.[30] In the context of X chromosome inactivation, ASOs designed to interact with the XIST lncRNA offer a unique approach. These ASOs aim to modulate XIST activity, potentially providing insights and therapeutic avenues for conditions associated with X chromosome abnormalities.[31] NEAT1, a lncRNA associated with nuclear paraspeckle formation and implicated in cancer progression, has been targeted using ASOs. The precise binding of ASOs to NEAT1 can alter its expression levels, presenting an avenue for therapeutic intervention in diseases where NEAT1 dysregulation is implicated.[32]

The lncRNA GAS5, involved in regulating cell growth and apoptosis, has been a target for ASOs. By interacting with GAS5, ASOs can potentially modulate its function, offering a strategy to influence cellular processes implicated in conditions such as cancer and neurodegenerative diseases. ASOs targeting ANRIL, a lncRNA associated with cell proliferation and implicated in cardiovascular diseases and cancers, have been explored. These ASOs aim to disrupt ANRIL's interactions, providing a potential therapeutic avenue for diseases where ANRIL dysregulation plays a role.[33,34] The success of ASOs in modulating the functions of these specific lncRNAs unlocks new possibilities for therapeutic interventions, offering a tailored approach to address the intricate regulatory networks involved in health and disease.

4.2 Small Interfering RNAs (siRNAs)

Small interfering RNAs (siRNAs) represent a class of short RNA molecules with potent capabilities in regulating gene expression, particularly by triggering the degradation of specific lncRNAs. The mechanism involves the guided recruitment of the RNA-induced silencing complex (RISC) to the precise target sequence within the lncRNA, leading to its selective degradation or silencing. The application of siRNAs in targeting disease-associated lncRNAs has garnered significant attention due to its potential therapeutic implications. One notable example is the targeting of the lncRNA HOTAIR, which is often implicated in various diseases, including cancer. In preclinical studies, siRNAs designed to specifically interact with HOTAIR have demonstrated remarkable effectiveness. By exploiting the sequence specificity of siRNAs, researchers can selectively

intervene in the expression and function of HOTAIR, thereby influencing critical cellular processes associated with disease progression.[35,36]

The success of siRNAs in preclinical studies has paved the way for exploring their therapeutic applications across a spectrum of conditions. Beyond HOTAIR, siRNAs can be tailored to target other disease-relevant lncRNAs, offering a versatile approach to modulate the intricate gene regulatory networks involved in diverse pathological states. The precision afforded by siRNAs in selectively silencing lncRNAs holds promise for developing targeted and personalized therapeutic strategies. As advancements in RNA interference technologies continue, siRNAs are poised to play a pivotal role in the ongoing pursuit of understanding and harnessing the therapeutic potential of lncRNAs in health and disease.[37]

4.3 Small Molecule Inhibitors

The prospect of using small molecules to modulate the functions of lncRNAs offers a nuanced and targeted approach to influence gene regulation. Small molecules can be strategically designed to interact with specific secondary structures or binding sites within lncRNAs, disrupting their interactions with proteins or other nucleic acids. However, the success of this approach hinges upon a comprehensive understanding of the intricate structure and function of the targeted lncRNA.[38]

This sophisticated strategy involves identifying key structural motifs or binding domains within the lncRNA, which serve as potential points of intervention for small molecules. By precisely tailoring these molecules to interact with these specific regions, researchers aim to either stabilize or destabilize the secondary structures of the lncRNA, consequently modulating its regulatory capabilities.[39] To employ small molecules effectively in targeting lncRNAs, researchers delve into the intricacies of the lncRNA's three-dimensional structure, binding partners, and functional roles within cellular processes. This requires advanced techniques such as structural biology, high-throughput screening, and computational modeling to unravel the complexities of lncRNA architecture.[40]

As the understanding of lncRNA structures advances, the design and optimization of small molecules tailored to modulate these structures provide a promising avenue for therapeutic innovation. The exploration of small molecules targeting lncRNAs exemplifies the continual efforts to unlock the therapeutic potential encoded within the non-coding regions of the genome.[41]

4.4 CRISPR-Cas9-Mediated Editing

The CRISPR-Cas9 system stands as a revolutionary tool in molecular biology, providing researchers with the capability to achieve precise genomic editing. This technology, derived from the bacterial immune system, enables the targeted modification or knockout of specific genomic sequences, including those encoding long non-coding RNAs (lncRNAs). The application of CRISPR-based approaches in the study of lncRNAs offers a powerful means to delve into their functional roles and holds significant potential for therapeutic applications.[42]

CRISPR-Cas9 operates by employing guide RNA molecules to direct the Cas9 enzyme to specific genomic loci. In the context of lncRNAs, researchers can design guide RNAs to target and modify the sequences responsible for encoding these non-coding RNA molecules. This precision allows for the creation of knockout models, where the expression of a particular lncRNA is entirely disrupted, or for the introduction of specific modifications to investigate the functional consequences of these alterations.[43,44] One of the notable advantages of CRISPR-based approaches is their ability to directly manipulate the genomic loci housing lncRNAs. This differs from other techniques that may focus on post-transcriptional regulation or functional interference. By targeting the DNA sequences encoding lncRNAs, researchers gain insights into the fundamental roles these non-coding transcripts play in various cellular processes.[45]

The application of CRISPR-Cas9 in lncRNA research has provided valuable information about the functional relevance of specific lncRNAs. Moreover, the potential therapeutic applications of this technology extend to conditions where dysregulated lncRNA expression contributes to disease states. Modifying or disrupting the genomic sequences of disease-associated lncRNAs holds promise for developing targeted therapeutic

interventions aimed at correcting the underlying genetic aberrations.

As CRISPR-based technologies continue to evolve, their precision in genomic editing and versatility in studying lncRNAs contribute to an expanding landscape of possibilities. The intersection of CRISPR-Cas9 and lncRNA research not only deepens our understanding of these enigmatic molecules but also initiates avenues for innovative therapeutic strategies tailored to address the intricate regulatory networks governed by lncRNAs.[46]

4.5 LncRNA-Mimicking Molecules

In the dynamic landscape of molecular medicine, a novel avenue has emerged with the exploration of synthetic molecules designed to mimic the functions of specific lncRNAs. These lncRNA-mimicking molecules stand as versatile tools capable of modulating cellular processes by acting as decoys, engaging in competitive binding with endogenous lncRNAs for interactions with proteins or other RNAs. The intricate design of these synthetic molecules necessitates a profound understanding of the underlying mechanisms of the targeted lncRNA's action.[47]

The rationale behind lncRNA-mimicking molecules lies in their ability to interfere with the intricate dance of molecular interactions within the cellular milieu. By closely resembling the structure and functional motifs of specific lncRNAs, these synthetic mimics can competitively engage with the molecular partners that the natural lncRNA would normally interact with. This competitive binding creates a decoy effect, diverting crucial cellular components from their native lncRNA interactions and consequently influencing cellular processes.[48] Designing effective lncRNA-mimicking molecules demands an in-depth comprehension of the targeted lncRNA's mechanism of action. Researchers delve into the intricate details of how the lncRNA orchestrates its regulatory functions, identifying key structural motifs and binding sites that can be replicated in the synthetic mimic. This intricate understanding enables the creation of molecules that faithfully imitate the behavior of the endogenous lncRNA, ensuring specificity and efficacy in their intended cellular functions.[49]

For example, these synthetic mimics compete with endogenous lncRNAs for binding to proteins or other RNAs. This interference can have profound consequences on various cellular processes, including gene expression, chromatin remodeling, and signal transduction pathways. The therapeutic potential of lncRNA-mimicking molecules extends to conditions where dysregulated lncRNA functions contribute to disease pathogenesis.[50]

4.6 Viral Vectors for lncRNA Delivery

In the realm of innovative therapeutic strategies, viral vectors have emerged as potent vehicles, meticulously engineered to transport therapeutic lncRNAs or RNA-based molecules to target cells. This groundbreaking approach holds particular significance in the context of restoring the expression of tumor-suppressive lncRNAs or introducing artificial lncRNAs with therapeutic functions, ushering in a new era of precision medicine.[51,52]

At the heart of this strategy lies the adept manipulation of viral vectors to serve as carriers for therapeutic cargo. Viruses, with their intrinsic ability to infiltrate and manipulate host cells, are harnessed as vehicles for delivering therapeutic payloads to the target tissues. The genetic material of the virus is modified, replacing its natural content with the therapeutic lncRNA or RNA-based molecules intended for delivery. This engineered viral vector, now stripped of its pathogenic potential, becomes a specialized delivery system, navigating through the intricacies of the biological terrain to reach and engage with the intended recipient cells. The rationale behind utilizing viral vectors for lncRNA delivery is rooted in their remarkable efficiency in transduction, enabling them to penetrate the cellular membrane and release their cargo into the cellular machinery. This approach is particularly pertinent in scenarios where the restoration of specific lncRNA expression is crucial for combating diseases, such as cancer, where the dysregulation of lncRNAs plays a pivotal role.[53]

Among the commonly employed viral vectors, adenovirus (AdV) stands out for its high transduction efficiency across diverse cell types, offering a robust means for delivering therapeutic lncRNAs with transient expression profiles.[54]

Adeno-associated virus (AAV) vectors, renowned for their safety and ability to mediate prolonged gene expression, emerge as a versatile choice suitable for both gene therapy applications and the delivery of lncRNAs. Lentiviral vectors, derived from human immunodeficiency virus (HIV), prove advantageous in achieving stable and enduring expression of lncRNAs, particularly in both dividing and non-dividing cells.[55]

Significant is the exploration of herpes simplex virus (HSV) vectors for their affinity to neuronal cells, holding promise for lncRNA delivery in neurological disorders where long-term expression in neurons is desirable.[56] Additionally, Sendai virus (SeV) vectors, known for their high delivery efficiency and low cytotoxicity, present a compelling option for versatile lncRNA delivery. The adaptable nature of baculoviral vectors, derived from insect viruses, extends their utility to mammalian cells for specific lncRNA applications.[57] Vesicular stomatitis virus (VSV) vectors, characterized by rapid and efficient gene delivery, show potential for delivering therapeutic lncRNAs in targeted contexts. The selection of a viral vector for lncRNA delivery is a nuanced decision, influenced by the specific requirements of the study or therapeutic application, and ongoing advancements in vector engineering continue to broaden the possibilities for effective lncRNA delivery using viral vectors.[58]

One noteworthy application of viral vectors in lncRNA therapeutics is the restoration of tumor-suppressive lncRNAs. In instances where these crucial regulators of cellular processes are downregulated or lost in disease states, viral vectors can deliver intact copies of these lncRNAs to reestablish their presence and functionality. The concept extends to the introduction of artificial lncRNAs engineered for therapeutic purposes, such as influencing gene expression, modulating cellular pathways, or targeting specific disease-related processes.[59]

4.7 Nanoparticle-Based Delivery Systems

In the dynamic landscape of drug delivery, nanoparticle-based systems have emerged as groundbreaking tools, providing an innovative approach to transport therapeutic agents, ranging from small molecules to nucleic acids, to target cells with unparalleled precision. Nanoparticles can encapsulate therapeutic payloads, shielding them from degradation and ensuring controlled release kinetics. This encapsulation not only enhances the stability of the delivered agents but also facilitates their targeted delivery to specific cells or tissues. The ability to engineer nanoparticles with surface modifications allows for enhanced cellular uptake and the potential to tailor the delivery system to the requirements of lncRNA-targeting agents.[60]

Nanoparticle-based systems are particularly promising in the context of delivering therapeutic agents that specifically target lncRNAs. One illustrative example of nanoparticle-based systems for delivering therapeutic agents targeting lncRNAs involves the encapsulation and delivery of small interfering RNAs (siRNAs). In the realm of cancer therapeutics, where aberrant lncRNA expression often fuels tumor growth, nanoparticle-mediated delivery of siRNAs provides a precise mechanism for modulating the expression of disease-associated lncRNAs.[61] Researchers design siRNAs to specifically target and degrade the lncRNA of interest. By encapsulating these siRNAs within nanoparticles, their controlled release at the tumor site becomes feasible, ensuring that the therapeutic payload reaches cancer cells with high specificity.[62]

5. PHARMACOKINETICS OF LncRNAs

Understanding of the pharmacokinetics of lncRNAs is vital in the development of therapeutic interventions targeting these molecules. The dynamic and inherently labile nature of lncRNAs necessitates a detailed examination of their pharmacokinetic profiles to ensure their stability and persistence within the biological milieu. Assessing the bioavailability of delivered lncRNAs is crucial for determining the fraction that reaches specific target tissues or cells, optimizing their concentrations for therapeutic efficacy.[32]

Moreover, insights into the distribution of therapeutic lncRNAs within tissues and cellular compartments are vital for achieving targeted delivery and minimizing off-target effects. Pharmacokinetic studies provide valuable information on the metabolism and elimination pathways of lncRNAs, guiding the design of delivery systems to prolong their presence and enhance

therapeutic sustainability. This knowledge contributes to dose optimization, ensuring that therapeutic lncRNAs are administered at appropriate levels, frequencies, and durations to achieve desired outcomes while maintaining safety and tolerability. In essence, unraveling the pharmacokinetics of lncRNAs serves as a foundational step in the development of precise, effective, and well-tolerated therapeutic interventions.[63]

5.1 Absorption

The method of delivering lncRNA-based therapeutics significantly influences absorption, and various administration routes, including intravenous, intramuscular, subcutaneous, or oral, may result in different absorption profiles. LncRNAs encounter biological barriers, such as the gastrointestinal tract or cell membranes, depending on the chosen route of administration.[64] Effectively overcoming challenges associated with the absorption of lncRNA-based therapeutics is crucial for optimizing their delivery and ensuring a meaningful therapeutic impact.

Several methods and strategies have been explored to address these challenges. Enhanced delivery vehicles, such as nanoparticles, offer a promising approach by protecting lncRNAs from degradation, enhancing stability, and facilitating efficient cellular uptake.[61] Liposomal formulations provide another avenue, encapsulating lncRNAs to shield them from enzymatic degradation and promoting absorption through cell membranes.[65]

Modification of lncRNA structure is a strategic consideration. Chemical modifications, like pseudouridylation or 2'-O-methylation, can enhance lncRNA stability, rendering them more resistant to nucleases and improving overall absorption.[66] Conjugation strategies involve linking lncRNAs with molecules, such as cell-penetrating peptides or aptamers, to enhance cellular uptake and improve absorption efficiency. Intracellular delivery techniques focus on enhancing uptake into the intracellular environment. Strategies such as endocytosis facilitation or designing lncRNAs with motifs that facilitate receptor-mediated endocytosis aim to improve cellular uptake and overall absorption.[67,68]

Optimizing administration routes is critical, with intravenous administration bypassing gastrointestinal barriers for rapid and efficient delivery to the bloodstream. Subcutaneous and intramuscular injections provide alternative routes that may offer sustained release and avoid first-pass metabolism, enhancing overall absorption.[69] Overcoming challenges in the gastrointestinal tract involves strategies such as enteric coating for orally administered lncRNA therapeutics. This protective coating shields lncRNAs from the acidic stomach environment, preventing premature degradation and improving absorption in the intestine.[70] Absorption enhancers, when used in oral formulations, can improve permeability across the intestinal mucosa, further enhancing absorption. Cellular uptake strategies, including the use of cell-penetrating peptides or exosome-mediated delivery, aim to facilitate direct entry into cells, overcoming membrane barriers and improving cellular uptake.[71,72]

Active targeting approaches, such as incorporating ligands or antibodies on the surface of lncRNA carriers, enable targeted delivery to specific cells or tissues. This enhances the localized delivery and absorption of therapeutic payloads.[73] These diverse absorption strategies of lncRNA-based therapeutics ultimately enhancing their bioavailability and effectiveness in modulating cellular processes for therapeutic purposes. Continuous advancements in delivery technologies and the understanding of cellular uptake mechanisms contribute to ongoing progress in overcoming absorption challenges in lncRNA therapeutics.

5.2 Distribution

LncRNAs display distinct tissue-specific distribution patterns, and the therapeutic effectiveness of lncRNA-based interventions relies heavily on their ability to reach specific target tissues or organs.[74] The mechanisms governing cellular uptake, including endocytosis or direct penetration, play a pivotal role in determining the intracellular distribution of lncRNAs. Overcoming challenges associated with the distribution of lncRNAs is crucial for maximizing their therapeutic impact. To address distribution challenges, current research has explored various methods and strategies, each designed to enhance the selective delivery of lncRNAs to target tissues. One approach involves

enhanced tissue targeting through ligand-mediated strategies, incorporating ligands or antibodies on the surface of lncRNA carriers to actively target specific cells or tissues. This facilitates tissue-specific distribution, ultimately improving the localized delivery of therapeutic payloads.[75]

Optimizing nanoparticle delivery represents another avenue. Surface modification of nanoparticles, such as PEGylation, influences their biodistribution, enhancing circulation time and promoting selective accumulation in target tissues.[76] Exosome-mediated delivery leverages endogenous cellular uptake mechanisms, capitalizing on naturally occurring exosomes to facilitate the transfer of lncRNAs between cells and contributing to their distribution within tissues.[77]

Strategies for intracellular trafficking enhancement focus on modifying lncRNA carriers to facilitate endosomal escape after cellular uptake, ensuring that delivered lncRNAs reach their intracellular targets effectively. Hydrogel-based delivery systems offer sustained release, promoting prolonged exposure of lncRNAs to target tissues and contributing to improved distribution over an extended period.[78,79] Local administration techniques, such as intra-tumoral injection for cancer therapies, enhance local distribution by ensuring a higher concentration of the therapeutic payload within the target tumor tissue.[80] Carrier size optimization is crucial, with the size-dependent distribution of lncRNA carriers influencing their extravasation from blood vessels and improving distribution to target tissues.[81]

Targeting the lymphatic system is particularly relevant for diseases involving lymphoid tissues. Exploiting lymphatic transport mechanisms enhances the distribution of lncRNAs to these specific tissues. Combining lncRNA therapeutics with imaging technologies allows real-time monitoring of their distribution in vivo, aiding researchers in optimizing delivery systems and understanding the dynamics of lncRNA distribution.[82]

Engineering cellular uptake mechanisms, such as enhancing endocytosis, contributes to a more widespread distribution of lncRNAs within tissues. These strategies aim to overcome challenges related to the distribution of lncRNA-based therapeutics, ultimately enhancing their selective delivery to target tissues or organs.

5.3 Metabolism

LncRNAs face the challenge of enzymatic degradation by nucleases, a factor that significantly influences their metabolic fate.[83] The stability of lncRNAs in the presence of nucleases is a critical consideration, impacting their duration of action and overall effectiveness within the intricate biological milieu of circulation or cellular environments. In the pursuit of optimizing the therapeutic potential of lncRNAs, strategies have been developed to overcome the hurdles posed by enzymatic degradation.

- **Chemical Modifications for Stability:** Introducing chemical modifications, such as 2'-O-methylation or pseudouridylation, to the structure of lncRNAs emerges as a promising strategy. These modifications enhance stability against nucleases, conferring resistance to enzymatic degradation and ensuring a prolonged duration of action for lncRNAs.[66]
- **Locked Nucleic Acids (LNAs) and Other Analogues:** Incorporating locked nucleic acids (LNAs) or other analogues into the sequence of lncRNAs provides a protective shield against nucleases. These structural modifications impart resistance to enzymatic cleavage, contributing to the metabolic stability of lncRNAs.[84]
- **Exosome-Mediated Protection:** Leveraging the natural packaging of lncRNAs into exosomes presents a unique protective mechanism. Exosomes, acting as carriers, shield lncRNAs from extracellular nucleases during circulation and facilitate their transfer between cells, enhancing metabolic stability.[85]
- **Encapsulation within Nanoparticles:** Nanoparticle-based delivery systems create a protective environment for lncRNAs, shielding them from nucleases. The encapsulation within nanoparticles not only safeguards lncRNAs during circulation but also enhances their metabolic stability within target cells, supporting sustained therapeutic impact.[86]
- **Stabilizing Modifications in Delivery Vehicles:** Modifying delivery vehicles, such as liposomes or nanoparticles, with stabilizing elements is crucial

for improving overall stability. These modifications contribute to the successful navigation of lncRNAs through the bloodstream, protecting them from nucleases and ensuring intact delivery to target cells.[87]

- **Avoiding Immune Activation:** Designing lncRNA sequences to minimize immune activation is essential for avoiding degradation by immune-related nucleases. Careful consideration of sequence motifs helps prevent triggering an immune response, ensuring prolonged stability and functional efficacy.[88]
- **Intracellular Stability Enhancement:** Strategies to enhance intracellular stability involve designing lncRNAs with structural features that resist degradation within the cellular environment. This may include modifications to the secondary structure or sequence motifs that confer resistance to intracellular nucleases, contributing to overall therapeutic success.[89]

5.4 Excretion

The excretion of lncRNAs plays a pivotal role in understanding their pharmacokinetics within the biological system. Small-sized lncRNAs may undergo renal clearance, providing insights into their systemic removal from the body. Moreover, biliary excretion becomes relevant, particularly for conjugated lncRNAs, shedding light on their elimination through the bile into the gastrointestinal tract. The hepatic clearance pathway gains importance for larger lncRNA molecules, as the liver actively processes and eliminates them from the systemic circulation, affecting the distribution and elimination dynamics.[90,91]

Various strategies, such as size modification and conjugation, are explored to influence the excretion routes, redirecting lncRNAs towards renal or biliary clearance. Thorough assessments of renal clearance parameters, biliary excretion pathways, modulating hepatic clearance mechanisms and utilizing nanoparticle-based delivery systems are essential for gaining insights into lncRNA elimination mechanisms. Extending the stability and half-life of lncRNAs in circulation through modifications or encapsulation strategies contributes to their pharmacokinetic characteristics, with mathematical models aiding in estimating half-life based on experimental data.[92]

6. ADVERSE REACTIONS AND TOXICITIES

The exploration of lncRNAs as potential therapeutic agents involves addressing concerns related to toxicity and potential side effects. While lncRNAs hold significant promise, it is crucial to thoroughly evaluate their safety profile to ensure their clinical application.

6.1 Off-Target Effects

Off-target effects in the context of lncRNA-based therapeutics refer to unintended interactions between the administered lncRNAs and non-target molecules. These interactions can potentially lead to undesirable outcomes, posing challenges to the specificity and safety of lncRNA interventions. Rigorous screening and optimization of lncRNA sequences are crucial strategies to minimize off-target effects and enhance the specificity of therapeutic interventions.

One manifestation of off-target effects is the unintended regulation of gene expression. If lncRNAs are not carefully designed, they might interact with unintended mRNA targets, leading to alterations in gene expression levels. A lncRNA designed to modulate the expression of a specific oncogene may unintentionally affect the expression of a tumor suppressor gene, leading to unintended consequences on cell growth and survival.[93,94] Off-target effects can also occur when lncRNAs interact with non-target components of cellular signaling pathways. Such interactions may disrupt the delicate balance of signaling cascades, impacting cellular responses and functions. For example, a lncRNA designed to regulate a specific pathway involved in inflammation may inadvertently interact with components of unrelated signaling pathways, leading to aberrant immune responses and inflammatory processes.[95]

Disruptions in cellular homeostasis may result from off-target effects, interfering with normal cellular functions. This can have unintended consequences on cellular processes such as proliferation, differentiation, or apoptosis. A lncRNA, due to its sequence or structure, may activate immune cells and induce an inflammatory response, causing unintended inflammation and tissue

damage. LncRNAs may exhibit non-specific binding to proteins, affecting the function and activity of proteins unrelated to the intended therapeutic target.

To minimize off-target effects, rigorous screening, and optimization of lncRNA sequences are essential. Computational tools can predict potential off-target interactions, allowing for the refinement of lncRNA designs. Experimental validation through in vitro and in vivo studies helps assess specificity and identify potential unintended interactions.

6.2 Immunogenicity

Immunogenicity refers to the ability of a substance, such as lncRNAs, to induce an immune response. When introduced into the body, lncRNAs may be recognized as foreign entities by the immune system, triggering immune responses that can lead to inflammation or other immune-related side effects. Immunogenicity can manifest as inflammatory responses, posing challenges to targeted tissues. Uncontrolled inflammation may compromise therapeutic goals and cause harm to normal tissues. Recognition of lncRNAs by immune cells, such as macrophages or dendritic cells, can lead to their activation, contributing to the overall immune response against the perceived foreign invader.[96]

Minimizing immunogenicity is crucial for the successful clinical application of lncRNA therapeutics. Strategies to achieve this involve optimizing sequences, introducing structural modifications, considering the impact of delivery systems, and rigorous in vitro and in vivo validation. Avoiding motifs recognized as foreign by the immune system, introducing modifications to lncRNA structures, and designing delivery systems that minimize immune recognition contribute to reducing lncRNA immunogenicity.

6.3 Dose-Dependent Effects

The potential for dose-dependent effects implies that the biological response to lncRNAs can vary, and achieving the desired therapeutic outcome requires a careful determination of the optimal dosage. The dosage of administered lncRNAs plays a pivotal role in achieving the desired therapeutic effects without causing unwanted side effects. For illustration, a lncRNA designed to inhibit the progression of a cancerous tumor may exhibit optimal efficacy at a specific dosage, and deviations from this threshold might result in insufficient therapeutic impact or non-specific toxicity in normal tissues. The duration of action of lncRNAs can be influenced by dosage, making it essential to consider the optimal dosing for sustained therapeutic effects without prolonged exposure-related issues.[97]

Strategies for dose optimization involve rigorous preclinical studies, including biomarker monitoring, adaptive clinical trial designs, and patient stratification. Monitoring biomarkers associated with therapeutic response and toxicity aids in dose optimization. Adaptive clinical trial designs allow for real-time adjustments to dosage based on emerging data, while patient stratification based on individual variations and disease states contributes to personalized dosing.

6.4 Delivery System-Related Toxicity

In the realm of lncRNA therapeutics, the choice of delivery systems, including nanoparticles or carriers, introduces an additional layer of complexity due to the potential for delivery system-related toxicity. The interaction between nanoparticles and cellular components can lead to cytotoxic effects on cells. Factors such as nanoparticle composition, size, and surface charge play pivotal roles in influencing this interaction, potentially causing cell damage or death. Cationic nanoparticles, known for their efficacy in facilitating cellular uptake. Despite their effectiveness, these nanoparticles may disrupt cell membranes, inducing cytotoxicity. Therefore, a critical aspect in ensuring the safety of lncRNA therapeutics is the thorough assessment of the biocompatibility of nanoparticles, particularly those with cationic properties, to prevent unintended harm to cells. Designing nanoparticles with biocompatible materials and incorporating surface modifications is a fundamental strategy to minimize cytotoxic effects associated with their use in lncRNA delivery. The selection of materials that are compatible with biological systems, coupled with surface modifications mimicking biological components, enhances the biocompatibility of nanoparticles.[98]

Biodistribution-related toxicity is another critical aspect associated with the distribution patterns of delivery systems within the body. The uneven

distribution of carriers may impact off-target tissues, potentially causing unintended toxicity. If a nanoparticle-based delivery system accumulates predominantly in the liver, concerns about hepatotoxicity may arise. Therefore, a thorough assessment of the biodistribution of carriers is vital to ensuring their safety and minimizing off-target effects.[100]

The application of immunosuppressive coatings to delivery systems represents an innovative approach to dampen immune responses triggered by the carriers. This strategy aims to prevent inflammatory reactions induced by the immune system's recognition of the delivery system. By incorporating immunosuppressive coatings, the therapeutic outcome becomes safer and more predictable, enhancing the overall success of lncRNA-based interventions.[101] These advanced strategies contribute to the development of safer and more effective delivery systems for lncRNA therapeutics, paving the way for their successful clinical implementation.

6.5 Genomic Stability

Ensuring the genomic stability of cells exposed to long non-coding RNAs (lncRNAs) is a critical aspect of their therapeutic development. Unintended genomic alterations or disruptions resulting from lncRNA exposure could have profound and long-lasting effect on cellular integrity, emphasizing the need for thorough evaluation and monitoring.[102]

One approach to safeguard genomic stability involves comprehensive genomic analyses to identify any potential off-target effects. High-throughput sequencing technologies, such as whole-genome sequencing and RNA sequencing, can be employed to assess changes in the cellular genome in response to lncRNA treatment. The use of genetically engineered cell lines or animal models with specific reporter systems can provide real-time insights into genomic stability. Incorporating fluorescent reporters linked to genomic stability markers can allow researchers to visualize and quantify any alterations in real-time. Integration of bioinformatics tools and computational analyses can assist in predicting genomic targets of lncRNAs and assessing their impact on cellular integrity.[103]

7. THERAPEUTIC APPLICATIONS OF LncRNAs

7.1 Regulatory Roles in Disease Pathways

LncRNAs play pivotal roles in the regulation of diverse cellular pathways, and their involvement extends to disease-related pathways. These multifaceted molecules exert their regulatory functions through various mechanisms, acting as molecular scaffolds, guides, or decoys to influence the activity of proteins and other RNAs. lncRNAs have emerged as key regulators with profound implications for conditions such as cancer, neurodegenerative disorders, and cardiovascular diseases (Fig. 3). Specific lncRNAs have been identified as critical players, exerting significant influence on disease progression and pathogenesis.

7.1.1 Cancer

In the intricate landscape of cancer biology, the role of long non-coding RNAs (lncRNAs) has come to the forefront, showcasing their influence on fundamental cellular processes and their potential significance as therapeutic targets. Within the realm of cancer, specific lncRNAs have been identified as key players, modulating critical processes such as cell proliferation, apoptosis, and immune response. One noteworthy example is the lncRNA MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1), which has been implicated in various cancers and is recognized for its association with metastatic processes. MALAT1 is known to influence cell migration, invasion, and metastasis, thereby contributing to the aggressiveness of cancer cells. Its overexpression has been observed in multiple cancer types, and its involvement in the promotion of metastasis underscores its significance as a potential therapeutic target.[104] Another prominent lncRNA in the cancer landscape is HOTAIR (HOX Transcript Antisense RNA). HOTAIR plays a crucial role in chromatin remodeling and the regulation of gene expression within cancer cells. This lncRNA has been associated with the progression of various cancers, acting as a bridge between chromatin-modifying complexes and the transcriptional machinery. Its dysregulation can lead to aberrant gene expression patterns, influencing the development and progression of cancer.[105]



Fig. 3: Regulatory roles of LncRNAs in different disease pathways

These examples highlight the dual nature of lncRNAs in cancer, where they can function as either oncogenic drivers or tumor suppressors, depending on the specific context and cellular environment. The intricate regulatory networks in which lncRNAs participate contribute to the complexity of cancer development and progression. Understanding the roles of specific lncRNAs, such as MALAT1 and HOTAIR, provides insights into the molecular mechanisms underlying cancer pathogenesis and offers potential avenues for targeted therapeutic interventions.

7.1.2 Neurodegenerative Disorders & Synaptic Plasticity

The dysregulation of specific lncRNAs has been implicated in various neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, shedding light on their potential roles as diagnostic markers or therapeutic targets.

LncRNAs contribute to the orchestration of regulatory networks governing neuronal function and survival. Dysregulation of these networks is a common feature in neurodegenerative disorders, leading to the progressive decline of neuronal health and cognitive functions.[106] NEAT1 (Nuclear-Enriched Abundant Transcript 1) is one such lncRNA that has been linked to Alzheimer's disease, a neurodegenerative disorder characterized by cognitive decline and memory loss. NEAT1 plays a role in the formation of nuclear paraspeckles, subnuclear structures associated with the regulation of gene expression.[107] Nuclear paraspeckles are dynamic structures within the cell nucleus that participate in the sequestration of RNA-binding proteins and the regulation of RNA metabolism. NEAT1's involvement in the formation and regulation of nuclear paraspeckles suggests a potential link between these structures and the pathological processes underlying Alzheimer's disease.[108]

The dysregulation of lncRNAs like NEAT1 may contribute to aberrant RNA metabolism within neurons, impacting the synthesis and processing of RNA molecules. This dysregulation, in turn, can lead to the accumulation of toxic protein aggregates and other molecular changes associated with neurodegeneration.[109,110] The identification of lncRNAs such as NEAT1 in the context of neurodegenerative disorders holds potential diagnostic implications. Monitoring the expression levels of these lncRNAs may provide insights into the progression of diseases and aid in early diagnosis. Furthermore, understanding their functional roles starts possibilities for the development of targeted therapeutic interventions.[111]

LncRNAs are involved in the regulation of neurite outgrowth, the process by which nerve cells extend their projections. Additionally, they contribute to synapse formation, influencing the establishment of connections between neurons. These processes are fundamental for the development and functioning of neural circuits.[112] Synaptic plasticity refers to the ability of synapses to undergo changes in strength and efficacy, crucial for learning and memory. LncRNAs contribute to the dynamic regulation of synaptic plasticity by modulating the expression of genes involved in synapse formation, maintenance, and activity-dependent changes. The lncRNA BC1 (Brain Cytoplasmic RNA 1) has been specifically associated with synaptic plasticity in the brain. BC1 is known to interact with translational machinery and modulate the local translation of proteins at synapses. This localized control of protein synthesis is essential for the dynamic changes in synaptic strength observed during plasticity.[113-115]

7.1.3 Cardiovascular Diseases

The dysregulation of long non-coding RNAs (lncRNAs) stands out as a significant contributor, exerting influence over crucial processes such as cardiac hypertrophy, angiogenesis, and inflammation. The intricate interplay between specific lncRNAs and cardiovascular pathogenesis sheds light on their potential as key regulators and therapeutic targets in the context of heart-related disorders.

One noteworthy lncRNA associated with cardiovascular diseases is ANRIL (Antisense Non-coding RNA in the INK4 Locus). ANRIL has been linked to atherosclerosis, a condition characterized by the accumulation of plaque in arterial walls, leading to impaired blood flow and increased risk of cardiovascular events. In the intricate web of molecular interactions, ANRIL plays a pivotal role in the regulation of vascular cell function and inflammation, contributing to the pathogenesis of cardiovascular diseases.[116]

LncRNAs have been implicated in the modulation of signaling pathways that govern cardiac hypertrophy, a condition where the heart muscle thickens in response to various stimuli, this process. The dysregulation of specific lncRNAs may contribute to the maladaptive remodeling of the heart, leading to impaired cardiac function. Moreover, certain lncRNAs participate in the intricate regulatory networks governing angiogenesis, influencing the balance between pro- and anti-angiogenic factors.[117]

7.1.4 Immune Disorders

One notable lncRNA with significant implications in immune system modulation is GAS5 (Growth Arrest-Specific 5), which exerts its influence on T cell proliferation and has been linked to autoimmune conditions such as rheumatoid arthritis.[118] GAS5 plays a pivotal role in orchestrating T cell responses, acting as a molecular player in the regulation of immune processes. T cells are integral components of the immune system responsible for orchestrating responses against pathogens and abnormal cells. The dysregulation of T cell function is a hallmark of autoimmune diseases, where the immune system mistakenly targets the body's own tissues.

GAS5 has been identified as a key lncRNA involved in disease pathogenesis of rheumatoid arthritis. Rheumatoid arthritis involves an aberrant immune response that leads to inflammation in the synovium, the lining of the joints. GAS5's modulation of T cell proliferation suggests its potential role in influencing the immune dysregulation observed in rheumatoid arthritis.[119] LncRNAs in immune disorders, particularly in autoimmune diseases like rheumatoid arthritis, underscores significance as regulators of immune system function.

7.1.5 Antiviral Action

The lncRNAs play diverse roles in inhibiting viral replication, modulating host factors, and orchestrating antiviral signaling pathways. Certain lncRNAs directly target and inhibit various stages of the viral replication cycle. They may interact with viral RNA or proteins, disrupting essential processes such as viral transcription, translation, or assembly.[120] By interfering with these key steps, lncRNAs serve as potent effectors in limiting the spread and propagation of viruses within host cells. The lncRNA NRON (non-coding repressor of NFAT) has been implicated in inhibiting human immunodeficiency virus 1 (HIV-1) replication by interacting with the viral transactivator protein Tat. NRON modulates Tat's activity, thereby suppressing viral gene expression and replication.[121]

LncRNAs play a pivotal role in activating antiviral signaling pathways, especially the interferon response. Upon viral infection, the host cells release interferons, which trigger a cascade of antiviral defenses. LncRNAs can regulate the expression of key genes involved in the interferon response, enhancing the cell's ability to counteract viral invaders. The lncRNA lincRNA-Cox2 is induced by interferons and acts as a positive regulator of antiviral responses. It promotes the expression of interferon-stimulated genes (ISGs) by facilitating the formation of enhancer-promoter loops, thereby enhancing the host cell's ability to combat viral infections.[122]

The lncRNA NEAT1 has been associated with the antiviral response by modulating the expression of interferon-stimulated genes. NEAT1 functions as a molecular scaffold that facilitates the assembly of antiviral signaling complexes, enhancing the activation of downstream effectors involved in the antiviral response.[123] LncRNAs participate in the epigenetic regulation of antiviral genes, influencing their chromatin state and transcriptional activity. The lncRNA THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) plays a role in the antiviral response by promoting the expression of genes involved in the innate immune response. THRIL interacts with the chromatin of target genes, facilitating their transcription and contributing to antiviral defense.[124]

7.2 Biomarkers for Disease Diagnosis and Prognosis

LncRNAs are pivotal biomarkers with diverse applications in disease diagnosis, prognosis, and therapeutic monitoring. Their unique expression patterns offer valuable insights into various physiological and pathological conditions. Altered expression of specific lncRNAs is a hallmark of diseases, making them valuable diagnostic biomarkers. For example, the upregulation of HOTAIR has been associated with various cancers, including breast and colorectal cancer, serving as a diagnostic indicator.[125] Tissue-specific lncRNAs, such as HULC in liver cancer, provide a targeted approach for disease identification.[126]

Changes in lncRNA expression correlate with disease progression, serving as prognostic markers. MALAT1, linked to metastasis in lung cancer, is a prognostic indicator for poor survival outcomes.[127] In breast cancer, overexpression of ANRIL predicts a higher risk of recurrence, aiding in prognostic assessments.[128] In leukemia, monitoring MALAT1 levels helps assess the response to chemotherapy.[129] Non-invasive monitoring using circulating lncRNAs, like PCA3 in prostate cancer, offers real-time assessment of treatment response.[130]

LncRNA dysregulation often precedes clinical symptoms, enabling early detection. The upregulation of UCA1 in urine samples serves as an early diagnostic marker for bladder cancer.[131] Similarly, the elevated expression of H19 in serum is associated with early-stage hepatocellular carcinoma.[132] In glioblastoma, the differential expression of TUG1 and H19 distinguishes between subtypes, contributing to more accurate diagnoses. In lung cancer, the lncRNA SPRY4-IT1 helps differentiate between histological subtypes.[133]

The versatility and accessibility of lncRNAs in various biological samples make them indispensable in advancing precision medicine and personalized healthcare. As our understanding of lncRNA biology deepens, their role as biomarkers will continue to expand, contributing to more effective diagnostic and therapeutic strategies.

7.3 Epigenetic Regulation and Chromatin Organization

LncRNAs involvement in key epigenetic processes, including DNA methylation, histone modification, and chromatin structure, highlights their significance in shaping the regulatory landscape of the genome. The dysregulation of these epigenetic processes is a hallmark of many diseases, and understanding the intricate involvement of lncRNAs in these mechanisms provides novel insights into potential therapeutic interventions. LncRNAs can guide DNA methyltransferases to specific genomic loci, influencing the addition or removal of methyl groups from DNA molecules. Dysregulation of DNA methylation is implicated in various diseases, including cancer and neurodegenerative disorders.[134]

Histone modification represents another layer of epigenetic regulation orchestrated by lncRNAs. LncRNAs can interact with chromatin-modifying

complexes and guide them to specific genomic regions, leading to alterations in histone acetylation, methylation, or other modifications. This intricate interplay between lncRNAs and histone modifiers contributes to the establishment of distinct chromatin states that govern gene activity. Perturbations in histone modifications are implicated in diseases such as cardiovascular disorders and autoimmune conditions.[135]

Chromatin structure, a fundamental aspect of gene regulation, is also subject to the influence of lncRNAs. Acting as molecular scaffolds, lncRNAs guide chromatin-modifying complexes to specific genomic sites, inducing changes in the three-dimensional organization of chromatin. This structural modulation affects the accessibility of genes to transcriptional machinery, ultimately influencing gene expression patterns. Dysregulation of chromatin organization mediated by lncRNAs has been implicated in diseases ranging from developmental disorders to various cancers.[136]

7.4 Stem Cell Maintenance and Pluripotency

MALAT1, or Metastasis-Associated Lung Adenocarcinoma Transcript 1, is one such lncRNA that has been implicated in the maintenance of embryonic stem cell pluripotency.[137] Studies have shown that MALAT1 is highly expressed in embryonic stem cells, suggesting a potential role in maintaining their pluripotent state. Pluripotency-associated transcription factors, such as OCT4, SOX2, and NANOG, are crucial for the identity of embryonic stem cells, and MALAT1 may contribute to the regulation of these factors. MALAT1 is known to interact with chromatin-modifying complexes and transcriptional regulators. It may participate in the epigenetic regulation of genes associated with pluripotency, influencing the chromatin structure and accessibility of key regulatory regions.[138]

The intricate signaling pathways that govern pluripotency and self-renewal are tightly regulated. MALAT1 may intersect with these pathways, acting as a molecular mediator or scaffold that facilitates communication between different signaling components, ultimately influencing stem cell fate. While maintaining stem cell pluripotency, MALAT1 may also play a role during differentiation processes. It might contribute to the timely activation or repression of specific genes required for the transition from a pluripotent state to lineage-committed cells. MALAT1 may interact with microRNAs or other lncRNAs, forming regulatory networks that fine-tune gene expression and influence the balance between pluripotency and differentiation.[139]

7.5 Drug Development

LncRNAs emerge as promising therapeutic targets, presenting opportunities for novel treatments across diverse diseases. Advances in CRISPR-Cas9 gene editing and RNA interference (RNAi) technologies enable precise manipulation of disease-associated lncRNAs, driving innovative therapeutic strategies. Targeting specific genomic loci with CRISPR-Cas9 allows potent interventions in lncRNA-related diseases. The development of drugs selectively modulating disease-associated lncRNAs aims for therapeutic efficacy while minimizing off-target effects, offering a targeted approach for disease intervention.

8. COMPLICATIONS IN LncRNA DEVELOPMENT AND THERAPEUTICS

8.1 Functional Redundancy and Overlapping

Functional redundancy among lncRNAs arises from the fact that multiple lncRNAs can regulate similar biological processes. This redundancy complicates the task of attributing specific functions to individual molecules. The challenge lies in deciphering the nuances of their interactions and understanding whether different lncRNAs act independently or synergistically in each biological pathway. Multiple lncRNAs, such as MALAT1 and NEAT1, have been implicated in the regulation of gene expression and exhibit functional redundancy in processes like alternative splicing and nuclear organization.[140]

8.2 Cell-Type and Tissue-Specificity

The cell-type and tissue-specific expression of lncRNAs add a layer of complexity to their study. To comprehensively understand the roles of lncRNAs, researchers need to conduct in-depth studies across various cell types and tissues. This involves not only identifying the specific cell types where a lncRNA is active but also considering the dynamic changes in expression across different physiological conditions within those cell types. The lncRNA HOTAIR is highly expressed in breast cancer tissues but not in normal

breast tissues, highlighting the cell-type and tissue-specific nature of lncRNA expression.[141]

8.3 Low Conservation Across Species

The low sequence conservation of lncRNAs across species poses challenges in extrapolating findings from one organism to another. Unlike protein-coding genes, which often exhibit higher conservation, lncRNAs may have unique functions specific to certain species. Understanding the evolutionary dynamics of lncRNAs and the divergence of their sequences across species becomes crucial for drawing accurate conclusions about their functions.[142] The lncRNA Xist, crucial for X chromosome inactivation in mammals, emphasizing the challenge of extrapolating findings across evolutionary boundaries.

8.4 Technical Challenges in Functional Studies

The technical challenges in studying lncRNA functions are multifaceted. The low expression levels of many lncRNAs make their detection and quantification challenging. Additionally, determining the precise cellular localization of lncRNAs is crucial for understanding their functions. Techniques such as single-cell RNA sequencing and advanced imaging methods are required to overcome these challenges and provide a more nuanced view of lncRNA biology. The lncRNA HOTTIP, crucial for development, is lowly expressed, posing challenges in functional characterization.[143]

8.5 Limited Structural Information

Unlike proteins, which often have well-defined three-dimensional structures, lncRNAs generally lack comprehensive structural information. Understanding the structural aspects of lncRNAs is vital for elucidating their interactions with proteins and other biomolecules. Advances in techniques like cryo-electron microscopy and nuclear magnetic resonance spectroscopy are essential for gaining insights into the structural biology of lncRNAs. While the structure of the lncRNA MALAT1 has been partially characterized, many other lncRNAs lack such detailed structural information.[38]

8.6 Dynamic Nature of RNA Molecules

The dynamic nature of RNA molecules, including lncRNAs, introduces challenges in studying them under changing cellular conditions. Rapid turnover and fluctuations in RNA levels necessitate experimental designs that capture the temporal dynamics. Longitudinal studies, time-course experiments, and the integration of quantitative approaches are essential for unraveling the regulatory roles of lncRNAs in dynamic cellular environments. The lncRNA GAS5 responds to cellular stress conditions by altering its expression levels, illustrating the dynamic nature of lncRNAs and the need for sophisticated experimental designs.[144]

8.7 Interactions with Multiple Molecules

LncRNAs often function by interacting with multiple partners simultaneously, including proteins, RNAs, and other biomolecules. Deciphering the specific interactions and their functional consequences requires sophisticated experimental techniques such as RNA-protein interaction assays, RNA pull-down assays, and cross-linking methods. Understanding the context-dependent nature of these interactions is crucial for unraveling the complexity of cellular networks. The lncRNA ANRIL interacts with chromatin-modifying proteins and microRNAs simultaneously, highlighting the intricate web of interactions lncRNAs have within cellular networks.[145]

8.8 Functional Annotation and Database Limitations

The ongoing challenge in the comprehensive functional annotation of lncRNAs is compounded by the lack of standardized nomenclature and functional annotations. This poses difficulties in data interpretation and integration across different studies. Initiatives to establish standardized guidelines for lncRNA naming and annotation are crucial for enhancing the accessibility and reliability of information in databases. Moreover, efforts to expand existing databases and create unified platforms for lncRNA information are essential for advancing our understanding of their functions. The lncRNA PCA3, associated with prostate cancer, faces challenges in functional annotation due to the lack of standardized nomenclature, complicating efforts to integrate information from various databases.[146]

9. CHALLENGES AND FUTURE DIRECTIONS

The field of lncRNA research has made remarkable progress, yet it grapples with various technical challenges. One such challenge is the complex

secondary structures adopted by lncRNAs, complicating their experimental characterization. These intricate folding patterns influence interactions with other molecules, making it challenging to identify functional domains accurately. Additionally, lncRNAs exhibit dynamic expression patterns in response to cellular conditions, requiring sophisticated experimental designs to capture these changes comprehensively. Ethical considerations play a pivotal role in lncRNA research, especially concerning potential off-target effects of lncRNA-targeted therapies. The specificity of these therapies raises concerns about unintended interactions with non-target molecules. Rigorous screening and optimization are essential to minimize off-target effects and enhance safety.

Pharmacokinetic aspects pose significant challenges in lncRNA research. Ensuring efficient delivery of lncRNA-targeting agents to specific cells or tissues is crucial for therapeutic efficacy. Factors such as stability in circulation and biodistribution influence the pharmacokinetics of these agents, requiring careful consideration. The integration of multi-omics data is a promising avenue for a more holistic understanding of lncRNA biology. Combining genomics, transcriptomics, proteomics, and epigenomics data can provide comprehensive insights into the complex regulatory networks involving lncRNAs.

Functional annotation of lncRNAs remains a critical aspect of future research. Advancements in methodologies such as CRISPR-based screening and high-throughput functional assays will contribute to a more detailed functional characterization of lncRNAs. Bridging the gap between basic research and clinical applications is another future direction. Establishing robust preclinical models, conducting safety assessments, and optimizing delivery systems are crucial steps toward realizing the clinical potential of lncRNA-targeted therapies. In navigating these challenges and embracing future directions, the field of lncRNA research holds tremendous potential for uncovering novel therapeutic strategies and expanding our understanding of gene regulation and cellular processes. Addressing technical, ethical, and pharmacokinetic considerations will be pivotal in realizing the clinical applications of lncRNA-based interventions.

10. CONCLUSION

In conclusion, the exploration of lncRNAs from biomarkers to pharmacological targets has illuminated the complex and multifaceted roles these molecules play in the realm of health and disease. This comprehensive review aims to provide a guiding beacon for researchers, clinicians, and pharmaceutical scientists venturing into the dynamic landscape of lncRNA research. In the era of personalized medicine, the profound potential of lncRNAs as diagnostic tools and therapeutic targets emerges as a beacon of hope for the future of disease intervention and drug development. The ongoing strides in understanding lncRNA biology pave the way for innovative approaches that could revolutionize clinical practice, offering new dimensions to precision medicine and ushering in an era of targeted and tailored therapeutic interventions.

Conflict of Interest: The authors declare that they have no conflicts of interest.

REFERENCES

1. Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: From disease code to drug role. Acta Pharm Sin B. 2021 Feb;11(2):340-354.
2. Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, Liu H, Fan T. Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers. Front Oncol. 2020;10:598817.
3. Karakas D, Ozpolat B. The Role of LncRNAs in Translation. Non-Coding RNA. 2021;7:16.
4. Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grützner F, Kaessmann H. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 2014 Jan 30;505(7485):635-40.
5. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013 Mar;193(3):651-69.
6. Ramírez-Colmenero A, Oktaba K, Fernandez-Valverde SL. Evolution of Genome-Organizing Long Non-coding RNAs in Metazoans. Front Genet. 2020;11:589697.
7. Hezroni H, Koppstein D, Schwartz MG, Avrutin A, Bartel DP, Ulitsky I. Principles of Long Noncoding

RNA Evolution Derived from Direct Comparison of Transcriptomes in 17 Species. Cell Reports. 2015;11(7):1110-1122.
8. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013 Jun;10(6):925-33.
9. Jarroux J, Morillon A, Pinskaya M. History, Discovery, and Classification of lncRNAs. In: Rao M (ed) Long Non Coding RNA Biology. Adv Exp Med Biol. 2017 Aug 17;1008.
10. Wen J, Liu Y, Shi Y, Huang H, Deng B, Xiao X. A classification model for lncRNA and mRNA based on k-mers and a convolutional neural network. BMC Bioinformatics. 2019 Sep 13;20:469.
11. Singh DK, Prasanth KV. Functional insights into the role of nuclear-retained long noncoding RNAs in gene expression control in mammalian cells. Chromosome Res. 2013 Dec;21(6-7):695-711.
12. Lucero L, Ferrero L, Fonouni-Farde C, Ariel F. Functional classification of plant long noncoding RNAs: a transcript is known by the company it keeps. New Phytologist. 2021;229:1251–1260.
13. McDonel P, Guttman M. Approaches for Understanding the Mechanisms of Long Noncoding RNA Regulation of Gene Expression. Cold Spring Harb Perspect Biol. 2019 Dec 2;11(12):a032151.
14. Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018 Mar 31;3(3):108-117.
15. Wang W, Min L, Qiu X, Wu X, Liu C, Ma J, Zhang D, Zhu L. Biological Function of Long Non-coding RNA (LncRNA) Xist. Front Cell Dev Biol. 2021 Jun 10;9:645647.
16. Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet. 2014 Aug;30(8):348-55.
17. Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta. 2015 Aug;1856(1):151-64.
18. Ghafouri-Fard S, Dashti S, Farsi M, Taheri M. HOX transcript antisense RNA: An oncogenic lncRNA in diverse malignancies. Experimental and Molecular Pathology. 2021;118:104578.
19. Morlando M, Fatica A. Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer. Int J Mol Sci. 2018 Feb 14;19(2):570.
20. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011 Apr 21;30(16):1956-62.
21. Yoon JH, Abdelmohsen K, Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol. 2013 Oct 9;425(19):3723-30.
22. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021 Feb;22:96–118.
23. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021 Feb 1;220(2):e202009045.
24. Zhang X, Hamblin MH, Yin KJ. The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017 Dec 2;14(12):1705-1714.
25. Pisignano G, Ladomery M. Epigenetic Regulation of Alternative Splicing: How LncRNAs Tailor the Message. Noncoding RNA. 2021 Mar 11;7(1):21.
26. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017 Aug 1;77(15):3965-3981.
27. Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, Shen F. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci. 2019 Nov 8;20(22):5573.
28. Samad MA, Pandiri K, Bojanapally AP. Antisense Oligonucleotides: Pharmacology and Delivery Strategies. Int J Appl Pharm Sci Res. 2020;5(1):1-6.
29. Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018 May 8;11(1):63.
30. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010 Apr 15;464(7291):1071-6.
31. Liu SJ, Lim DA. Modulating the expression of long non-coding RNAs for functional studies. EMBO Rep. 2018;19:e46955.

32. Arun G, Diermeier SD, Spector DL. Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med. 2018 Mar;24(3):257-277.
33. Zhou Y, Chen B. GAS5-mediated regulation of cell signaling (Review). Mol Med Rep. 2020 Oct;22(4):3049-3056.
34. Gomes CPC, Spencer H, Ford KL, Michel LYM, Baker AH, Emanueli C, Balligand J-L, Devaux Y. The Function and Therapeutic Potential of Long Non-coding RNAs in Cardiovascular Development and Disease. Mol Ther Nucleic Acids. 2017 Sep;8:494-507.
35. Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011 Jun 1;90(3):430-40.
36. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018 Mar;37(1):107-124.
37. Nukala SB, Jousma J, Cho Y, Lee WH, Ong SG. Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology. Cell Biosci. 2022 Mar 4;12:24.
38. Nguyen LD, Chau RK, Krichevsky AM. Small Molecule Drugs Targeting Non-Coding RNAs as Treatments for Alzheimer's Disease and Related Dementias. Genes (Basel). 2021 Dec 17;12(12):2005.
39. Donlic A, Hargrove AE. Targeting RNA in mammalian systems with small molecules. Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1477.
40. Peng Z, Liu C, Wu M. New insights into long noncoding RNAs and their roles in glioma. Mol Cancer. 2018;17:61.
41. Sun M, Kraus WL. From Discovery to Function: The Expanding Roles of Long Noncoding RNAs in Physiology and Disease. Endocrine Reviews. 2015;36(1):25–64.
42. Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Arch Dis Child Educ Pract Ed. 2016 Aug;101(4):213-5.
43. Xu Y, Li Z. CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020 Sep 8;18:2401-2415.
44. Hansmeier NR, Widdershooven PJM, Khani S, Kornfeld JW. Rapid Generation of Long Noncoding RNA Knockout Mice Using CRISPR/Cas9 Technology. Noncoding RNA. 2019 Jan 23;5(1):12.
45. Hazan J, Bester AC. CRISPR-Based Approaches for the High-Throughput Characterization of Long Non-Coding RNAs. Noncoding RNA. 2021 Dec 13;7(4):79.
46. Zhen S, Li X. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research. Hum Gene Ther. 2019 Jan;30(1):3-9.
47. Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N, Hahne JC. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Target Oncol. 2020 Jun;15(3):261-278.
48. Hu G, Niu F, Humburg BA, Liao K, Bendi S, Callen S, Fox HS, Buch S. Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget. 2018 Jan 1;9(26):18648-18663.
49. Du Z, Wen X, Wang Y, Jia L, Zhang S, Liu Y, Zhou L, Li H, Yang W, Wang C, Chen J, Hao Y, Salgado Figueroa D, Chen H, Li D, Chen N, Celik I, Zhu Y, Yan Z, Fu C, Liu S, Jiao B, Wang Z, Zhang H, Gülsoy G, Luo J, Qin B, Gao S, Kapranov P, Esteban MA, Zhang S, Li W, Ay F, Chen R, Hoffman AR, Cui J, Hu JF. Chromatin lncRNA Platr10 controls stem cell pluripotency by coordinating an intrachromosomal regulatory network. Genome Biol. 2021 Aug 19;22(1):233.
50. Xu T, Lin CM, Cheng SQ, Min J, Li L, Meng XM, Huang C, Zhang L, Deng ZY, Li J. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star. Mol Cancer. 2018 July 23;17:103.
51. Schwarzmueller L, Bril O, Vermeulen L, Léveillé N. Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. Cancers (Basel). 2020 Dec 19;12(12):3843.
52. Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, Talpur HS, Yang L. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer. Cell Physiol Biochem. 2017 Dec 18;44(3):948-966.
53. O'Driscoll CM, Bernkop-Schnürch A, Friedl JD, Préat V, Jannin V. Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this? Eur J Pharm Sci. 2019;133:190-204.
54. Hudry E, Vandenberghe LH. Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. Neuron. 2019 Mar 6;101.

55. Sertkaya H, Ficarelli M, Sweeney NP, Parker H, Vink CA, Swanson CM. HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency. Sci Rep. 2021 Jun 8;11(1):12067.
56. Artusi S, Miyagawa Y, Goins WF, Cohen JB, Glorioso JC. Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. Diseases. 2018 Aug 14;6(3):74.
57. Russell CJ, Hurwitz JL. Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses. Viruses. 2021;13:1023.
58. Ma Y, Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol. 2011 Mar;85(6):2942-52.
59. Policarpo R, Sierksma A, De Strooper B, d'Ydewalle C. (2021) From Junk to Function: LncRNAs in CNS Health and Disease. Front Mol Neurosci. 14:714768.
60. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016 Aug 19;44(14):6518-48.
61. Alzhrani R, Alsaab HO, Petrovici A, Bhise K, Vanamala K, Sau S, Krinock MJ, Iyer AK. Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems. Drug Discov Today. 2020 Apr;25(4):718-730.
62. Swaminathan G, Shigna A, Kumar A, Byroju VV, Durgempudi VR, Dinesh Kumar L. RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics. Front Nanotechnol. 2021;3:694838.
63. Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019 Nov;9(6):1113-1144.
64. Chen S, Zhang C, He B, He R, Xu L, Zhang S. The Role of lncRNAs in Regulating the Intestinal Mucosal Mechanical Barrier. Biomed Res Int. 2021 Nov 15;2021:2294942.
65. Dos Santos Rodrigues B, Banerjee A, Kanekiyo T, Singh J. Functionalized liposomal nanoparticles for efficient gene delivery system to neuronal cell transfection. Int J Pharm. 2019 Jul 20;566:717-730.
66. Diamantopoulos MA, Tsiakanikas P, Scorilas A. Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Ann Transl Med. 2018;6(12):241.
67. Azevedo C, Macedo MH, Sarmento B. Strategies for the enhanced intracellular delivery of nanomaterials. Drug Discov Today. 2018 May;23(5):944-959.
68. Sousa de Almeida M , Susnik E , Drasler B , Taladriz-Blanco P , Petri-Fink A , Rothen-Rutishauser B . Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev. 2021 May 7;50(9):5397-5434.
69. Lorscheider M, Gaudin A, Nakhlé J, Veiman K-L, Richard J, Chassaing C. Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Therapeutic Delivery. 2021;12(1):55-76.
70. Ekine-Afolabi BA, Njan AA, Rotimi SO, R I A, Elbehi AM, Cash E, Adeyeye A. The Impact of Diet on the Involvement of Non-Coding RNAs, Extracellular Vesicles, and Gut Microbiome-Virome in Colorectal Cancer Initiation and Progression. Front Oncol. 2020 Dec 14;10:583372.
71. Maher S, Brayden DJ, Casettari L, Illum L. Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics. 2019 Jan 19;11(1):41.
72. Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, Yang Z. Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application. Front Pharmacol. 2020;11:697.
73. Yoo J, Park C, Yi G, Lee D, Koo H. Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers (Basel). 2019 May 8;11(5):640.
74. Fan J, Saft M, Sadanandan N, Gonzales-Portillo B, Park YJ, Sanberg PR, Borlongan CV, Luo Y. LncRNAs Stand as Potent Biomarkers and Therapeutic Targets for Stroke. Front Aging Neurosci. 2020 Oct 19;12:594571.
75. Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, Bradbury AR, Arap W, Pasqualini R. Ligand-targeted theranostic nanomedicines against cancer. J Control Release. 2016;240:267-286.

76. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51.
77. Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022 Apr 19;7(1):166.
78. Hueso M, Mallén A, Suñé-Pou M, Aran JM, Suñé-Negre JM, Navarro E. ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery. Int J Mol Sci. 2021 Oct 27;22(21):11596.
79. Chen M, Zhang Y, Zhang W, Li J. Polyhedral Oligomeric Silsesquioxane-Incorporated Gelatin Hydrogel Promotes Angiogenesis during Vascularized Bone Regeneration. ACS Appl Mater Interfaces. 2020;12(20):22410-22425.
80. Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Convergence. 2019 July 15;6:23.
81. Sharma RK, Calderon C, Vivas-Mejia PE. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. Front Med Technol. 2021 Aug 10;3:678593.
82. Qiao H, Wu J, Zhang X, Luo J, Wang H, Ming D. The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System. Front Chem. 2021;9:786354.
83. Schwarzmueller L, Bril O, Vermeulen L, Léveillé N. Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. Cancers (Basel). 2020 Dec 19;12(12):3843.
84. Chen WK, Yu XH, Yang W, Wang C, He WS, Yan YG, Zhang J, Wang WJ. lncRNAs: novel players in intervertebral disc degeneration and osteoarthritis. Cell Prolif. 2017 Feb;50(1):e12313.
85. Kołat D, Hammouz R, Bednarek AK, Płuciennik E. Exosomes as carriers transporting long non-coding RNAs: Molecular characteristics and their function in cancer (Review). Mol Med Rep. 2019 Aug;20(2):851-862.
86. Piperno A, Sciortino MT, Giusto E, Montesi M, Panseri S, Scala A. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. Int J Nanomedicine. 2021 Aug 31;16:5981-6002.
87. Gao W, Hu CM, Fang RH, Zhang L. Liposome-like Nanostructures for Drug Delivery. J Mater Chem B. 2013 Dec 28;1(48):10.1039/C3TB21238F.
88. Wang P. The Opening of Pandora's Box: An Emerging Role of Long Noncoding RNA in Viral Infections. Front Immunol. 2019;9:3138.
89. Grillone K, Riillo C, Scionti F, Rocca R, Tradigo G, Guzzi PH, Alcaro S, Di Martino MT, Tagliaferri P, Tassone P. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic "dark matter". J Exp Clin Cancer Res. 2020 June 20;39:117.
90. Lu S, Su Z, Fu W, Cui Z, Jiang X, Tai S. Altered expression of long non-coding RNA GAS5 in digestive tumors. Biosci Rep. 2019 Jan 18;39(1):BSR20180789.
91. Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020 Apr 20;19:77.
92. Mahpour A, Mullen AC. Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy. JHEP Rep. 2020 Sep 3;3(1):100177.
93. Cuevas-Diaz Duran R, Wei H, Kim DH, Wu JQ. Invited Review: Long non-coding RNAs: important regulators in the development, function and disorders of the central nervous system. Neuropathol Appl Neurobiol. 2019 Oct;45(6):538-556.
94. Guzel E, Okyay TM, Yalcinkaya B, Karacaoglu S, Gocmen M, Akcakuyu MH. Tumor suppressor and oncogenic role of long non-coding RNAs in cancer. North Clin Istanb. 2019 Nov 22;7(1):81-86.
95. Zhao Q, Pang G, Yang L, Chen S, Xu R, Shao W. Long Noncoding RNAs Regulate the Inflammatory Responses of Macrophages. Cells. 2021 Dec 21;11(1):5.
96. Walther K, Schulte LN. The role of lncRNAs in innate immunity and inflammation. RNA Biol. 2021 May;18(5):587-603.
97. Borkiewicz L, Kalafut J, Dudziak K, Przybyszewska-Podstawka A, Telejko I. Decoding LncRNAs. Cancers (Basel). 2021 May 27;13(11):2643.
98. Villanueva-Flores F, Castro-Lugo A, Ramírez OT, Palomares LA. Understanding cellular interactions with nanomaterials: towards a

rational design of medical nanodevices. Nanotechnology. 2020 Mar 27;31(13):132002.
99. Badrigilan S, Heydarpanahi F, Choupani J, Jaymand M, Samadian H, Hoseini-Ghahfarokhi M, Webster TJ, Tayebi L. A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials. Int J Nanomedicine. 2020 Sep 25;15:7079-7096.
100. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196.
101. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics — challenges and potential solutions. Nat Rev Drug Discov. 2021 Aug;20:629–651.
102. Wang Y, Yan K, Wang L, Bi J. Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology. BMC Cancer. 2021 Jun 24;21(1):727.
103. Li S, Chen LX, Peng XH, Wang C, Qin BY, Tan D, Han CX, Yang H, Ren XN, Liu F, Xu CH, Zhou XH. Overview of the reporter genes and reporter mouse models. Animal Model Exp Med. 2018 Apr 19;1(1):29-35.
104. Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757-6768.
105. Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015 Mar;12(1):1-9.
106. Zhou S, Yu X, Wang M, Meng Y, Song D, Yang H, Wang D, Bi J, Xu S. Long Non-coding RNAs in Pathogenesis of Neurodegenerative Diseases. Front Cell Dev Biol. 2021 Aug 30;9:719247.
107. Ghafouri-Fard S, Taheri M. Nuclear Enriched Abundant Transcript 1 (NEAT1): A long non-coding RNA with diverse functions in tumorigenesis. Biomed Pharmacother. 2019 Mar;111:51-59.
108. Pisani G, Baron B. Nuclear paraspeckles function in mediating gene regulatory and apoptotic pathways. Noncoding RNA Res. 2019 Nov 21;4(4):128-134.
109. Asadi MR, Hassani M, Kiani S, Sabaie H, Moslehian MS, Kazemi M, Ghafouri-Fard S, Taheri M, Rezazadeh M. The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review. Front Aging Neurosci. 2021 Sep 21;13:709568.
110. Pereira Fernandes D, Bitar M, Jacobs FMJ, Barry G. Long Non-Coding RNAs in Neuronal Aging. Non-Coding RNA. 2018;4:12.
111. Prinz F, Kapeller A, Pichler M, Klec C. The Implications of the Long Non-Coding RNA *NEAT1* in Non-Cancerous Diseases. Int J Mol Sci. 2019 Feb 1;20(3):627.
112. Zimmer-Bensch G. Emerging Roles of Long Non-Coding RNAs as Drivers of Brain Evolution. Cells. 2019 Nov 6;8(11):1399.
113. Stampanoni Bassi M, Iezzi E, Gilio L, Centonze D, Buttari F. Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology. Int J Mol Sci. 2019 Dec 8;20(24):6193.
114. Ramirez A, Arbuckle MR. Synaptic Plasticity: The Role of Learning and Unlearning in Addiction and Beyond. Biol Psychiatry. 2016 Nov 1;80(9):e73-e75.
115. Rusconi F, Battaglioli E, Venturin M. Psychiatric Disorders and lncRNAs: A Synaptic Match. Int J Mol Sci. 2020 Apr 25;21(9):3030.
116. Wang Q, Zhao J, Chang H, Liu X, Zhu R. Association between lncRNA ANRIL genetic variants with the susceptibility to ischemic stroke: From a case-control study to meta-analysis. Medicine (Baltimore). 2021 Mar 19;100(11):e25113.
117. Liu L, Zhang D, Li Y. LncRNAs in cardiac hypertrophy: From basic science to clinical application. J Cell Mol Med. 2020 Oct;24(20):11638-11645.
118. Zhou Z, Chen J, Huang Y, Liu D, Chen S, Qin S. Long Noncoding RNA *GAS5*: A New Factor Involved in Bone Diseases. Front Cell Dev Biol. 2022 Jan 26;9:807419.
119. Moharamoghli M, Hassan-Zadeh V, Dolatshahi E, Alizadeh Z, Farazmand A. The expression of GAS5, THRIL, and RMRP lncRNAs is increased in T cells of patients with rheumatoid arthritis. Clin Rheumatol. 2019 Nov;38(11):3073-3080.
120. Yang Q, Lin F, Wang Y, Zeng M, Luo M. Long Noncoding RNAs as Emerging Regulators of COVID-19. Front Immunol. 2021 Aug 2;12:700184.
121. Li J, Chen C, Ma X, Geng G, Liu B, Zhang Y, Zhang S, Zhong F, Liu C, Yin Y, Cai W, Zhang H. Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation. Nat Commun. 2016 June 13;7:11730.

122. Ouyang J, Hu J, Chen JL. lncRNAs regulate the innate immune response to viral infection. Wiley Interdiscip Rev RNA. 2016 Jan-Feb;7(1):129-43.
123. Qiu L, Wang T, Tang Q, Li G, Wu P, Chen K. Long Non-coding RNAs: Regulators of Viral Infection and the Interferon Antiviral Response. Front Microbiol. 2018 Jul 19;9:1621.
124. Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, Head SR, Burns JC, Rana TM. The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1002-7.
125. Tang Q, Hann SS. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol Biochem. 2018 Jul 26;47(3):893-913.
126. Zhang H, Liao Z, Liu F, Su C, Zhu H, Li Y, Tao R, Liang H, Zhang B, Zhang X. Long noncoding RNA HULC promotes hepatocellular carcinoma progression. Aging (Albany NY). 2019 Oct 23;11(20):9111-9127.
127. Guo L, Zhang X, Pan H, Li Y, Wang J, Li L, Dong Y, Du X, Chen J, Guo F. Prognostic and immunological significance of metastasis associated lung adenocarcinoma transcript 1 among different kinds of cancers. Bioengineered. 2021 Dec;12(1):4247-4258.
128. Lu C, Wei D, Zhang Y, Wang P, Zhang W. Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects. Front Oncol. 2021 Aug 30;11:710538.
129. Fu S, Wang Y, Li H, Chen L, Liu Q. Regulatory Networks of LncRNA MALAT-1 in Cancer. Cancer Manag Res. 2020 Oct 15;12:10181-10198.
130. Helsmoortel H, Everaert C, Lumen N, Ost P, Vandesompele J. Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope? Noncoding RNA Res. 2018 May 23;3(2):64-74.
131. Ding Z, Ying W, He Y, Chen X, Jiao Y, Wang J, Zhou X. lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis. Medicine (Baltimore). 2021 Mar 19;100(11):e24805.
132. Tietze L, Kessler SM. The Good, the Bad, the Question-*H19* in Hepatocellular Carcinoma. Cancers (Basel). 2020 May 16;12(5):1261.
133. Jiang J, Lu Y, Zhang F, Huang J, Ren XL, Zhang R. The Emerging Roles of Long Noncoding RNAs as Hallmarks of Lung Cancer. Front Oncol. 2021 Oct 7;11:761582.
134. Zhao Y, Sun H, Wang H. Long noncoding RNAs in DNA methylation: new players stepping into the old game. Cell Biosci. 2016 Jul 11;6:45.
135. Bure IV, Nemtsova MV, Kuznetsova EB. Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis. Int J Mol Sci. 2022 May 22;23(10):5801.
136. Böhmdorfer G, Wierzbicki AT. Control of Chromatin Structure by Long Noncoding RNA. Trends Cell Biol. 2015 Oct;25(10):623-632.
137. Tiansheng G, Junming H, Xiaoyun W, Peixi C, Shaoshan D, Qianping C. lncRNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer Cells via Down-Regulating miR-202 Expression. Cell J. 2020 Oct;22(3):375-385.
138. Chen X, He L, Zhao Y, Li Y, Zhang S, Sun K, So K, Chen F, Zhou L, Lu L, Wang L, Zhu X, Bao X, Esteban MA, Nakagawa S, Prasanth KV, Wu Z, Sun H, Wang H. Malat1 regulates myogenic differentiation and muscle regeneration through modulating MyoD transcriptional activity. Cell Discov. 2017 Jan 17;3:17002.
139. Matsui WH. Cancer stem cell signaling pathways. Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S8-S19.
140. Gao F, Cai Y, Kapranov P, Xu D. Reverse-genetics studies of lncRNAs-what we have learnt and paths forward. Genome Biol. 2020 Apr 14;21(1):93.
141. Clark BS, Blackshaw S. Understanding the Role of lncRNAs in Nervous System Development. Adv Exp Med Biol. 2017;1008:253-282.
142. Johnsson P, Lipovich L, Grandér D, Morris KV. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta. 2014 Mar;1840(3):1063-71.
143. Alessio E, Bonadio RS, Buson L, Chemello F, Cagnin S. A Single Cell but Many Different Transcripts: A Journey into the World of Long Non-Coding RNAs. Int J Mol Sci. 2020 Jan 1;21(1):302.
144. Jones AN, Sattler M. Challenges and perspectives for structural biology of lncRNAs-the example of the Xist lncRNA A-repeats. J Mol Cell Biol. 2019 Oct 25;11(10):845-859.

145. Huang H, Li L, Wen K. Interactions between long non-coding RNAs and RNA-binding proteins in cancer (Review). Oncol Rep. 2021 Dec;46(6):256.

146. St Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015 May;31(5):239-51.

Cite the Article as: Valli ASS. From Biomarkers to Pharmacological Targets: Long Non-Coding RNAs in Disease Intervention and Drug Development. J Drug Vigil Altern Ther. 2022 Dec 30;2(2):56-81.